Immunome (IMNM) Cash from Financing Activities (2019 - 2026)

Immunome has reported Cash from Financing Activities for 8 years, with the latest figure at -$135000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 100.08% year-over-year to -$135000.0; the trailing twelve-month figure through Mar 2026 stood at $478.0 million (up 160.75% YoY), and the FY2025 full-year result was $640.4 million, up 166.23% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$135000.0, down from $432.8 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $432.8 million in Q4 2025, with the low at -$135000.0 in Q1 2026.
• Historically, Cash from Financing Activities has averaged $76.7 million across 5 years, with a median of $20.1 million in 2024.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 645326.47% — and 2025, when it tumbled 107.93%.
• Immunome's Cash from Financing Activities stood at $32000.0 in 2022, then jumped by 173334.38% to $55.5 million in 2023, then tumbled by 63.81% to $20.1 million in 2024, then surged by 2054.82% to $432.8 million in 2025, then plunged by 100.03% to -$135000.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$135000.0 (Q1 2026), $432.8 million (Q4 2025), and $45.4 million (Q3 2025), per Business Quant data.